[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hematopoietic-stem-cell-transplantation-hsct\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hematopoietic-stem-cell-transplantation-hsct":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,49,85,112,139,170,208,236],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100595104","impact-of-iron-overload-on-the-incidence-of-liver-complications-in-long-term-survivors-10-years-of-allogeneic-hematopoietic-stem-cell-transplantation-100595104",false,"NCT07028112","Impact of Iron Overload on the Incidence of Liver Complications in Long-Term Survivors (≥10 Years) of Allogeneic Hematopoietic Stem-Cell Transplantation.","Impact de la Surcharge en Fer Sur l'Incidence Des Complications hépatiques Chez Les Patients allogreffés de Cellules Souches hématopoïétiques à Plus de 10 Ans de la Greffe","AlloFer","Inclusion Criteria:\n\n* Age ≥ 18 years at enrollment\n* Allogeneic HSCT performed at Hôpital Saint Louis between 2004\u002F01\u002F01 and 2014\u002F12\u002F31\n* Alive and attending routine annual follow up within the two years of the study\n* Having given his non-opposition to study after understand overall aims\n* With health insurance coverage\n* Follow up consultation at Saint-Louis Hospital\n\nExclusion Criteria:\n\n* Patient under legal protection (protection of the court, or in curatorship or guardianship).\n\nnot in relapse of the hematological disease at the time of inclusion.\n\n• Patients under 45 Kg","ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","OBSERVATIONAL","This single-center, non interventional cohort study investigates whether chronic iron overload influences the incidence of liver complications in adults who are at least 10 years beyond allogeneic hematopoietic stem cell transplantation (allo HSCT). Approximately 400-500 survivors transplanted at Hôpital Saint Louis between January 2004 and December 2014 will be evaluated. Transplant characteristics, prior iron overload therapy, and historical hepatic events will be collected through the Promise database. At the same time, the prospective visit will include laboratory panels and non invasive liver stiffness measurement by FibroScan or shear wave elastography. The study's primary objective is to assess the impact of iron overload on the incidence of hepatic complications in patients more than 10 years after an allogeneic hematopoietic stem cell transplantation. Secondary aims include describing the spectrum and frequency of hepatic complications, determining risk factors (including graft versus host disease, conditioning regimen, and comorbidities), and evaluating the long term effectiveness of previous iron reduction treatments (phlebotomy or chelation). Results will clarify whether monitoring and treating iron overload in long term allo HSCT survivors can prevent late hepatic morbidity.",[25,26,27,28],"Iron Overload","Hemosiderosis","Liver Diseases","Hematopoietic Stem Cell Transplantation (HSCT)",[30,31,32,33,34,35],"Iron overload","Liver fibrosis","Elastography","Long-term complications","Allogeneic hematopoietic stem-cell transplantation","graft-versus-host disease","RECRUITING","2026-04-22",{"date":39,"type":40},"2026-04-27","ACTUAL",{"date":42,"type":40},"2025-08-20",{"date":44,"type":21},"2027-08-20",{"name":46,"class":47},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":70,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100584654","massage-impact-on-sleep-in-pediatric-oncology-100584654","NCT06892158","Massage Impact on Sleep in Pediatric Oncology","Massage Impact on Sleep in Hospitalization for Pediatric Oncology and Stem Cell Transplant Patients","Inclusion Criteria:\n\n1. Diagnosis of cancer, such as acute myeloid leukemia (AML) or relapsed acute lymphoblastic leukemia (rALL) OR admitted to receive autologous or allogeneic HSCT for any indication\n2. Expected to be an inpatient for at least 21 days\n3. Aged 12 to 21 years at enrollment.\n4. Inpatient at Children's National or Children's Hospital of Philadelphia (CHOP).\n\nExclusion Criteria:\n\n1. Cognitive impairment sufficient to preclude completing questionnaires appropriately\n2. Insufficient knowledge of English or Spanish that would prohibit completing the study instruments\n3. Previous enrollment","12 Years","21 Years",{"count":59,"type":21},70,"INTERVENTIONAL",[62],"NA","This study aims to determine the impact of massage therapy for pediatric patients receiving intensive chemotherapy or stem cell transplant (SCT).",[65,66,67,68,69,28],"Cancer","Pediatric Cancer","Chemotherapy Effect","Acute Myeloid Leukemia","Acute Lymphoblastic Leukemia, Pediatric",[71,72,73,74],"Stem cell transplant (SCT)","Decreased sleep efficiency","Pediatric cancer diagnosis","Circadian activity rhythm (CAR)","2026-04-13",{"date":77,"type":40},"2026-04-15",{"date":79,"type":40},"2025-01-23",{"date":81,"type":21},"2028-07",{"name":83,"class":47},"Children's Hospital of Philadelphia",2,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":60,"phases":96,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100415591","phase-1-adoptive-t-lymphocyte-administration-for-chronic-norovirus-treatment-in-immunocompromised-hosts-100415591","NCT04691622","Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts","ATLANTIC","Inclusion Criteria:\n\nParticipant Inclusion Criteria for NST Infusion:\n\n1. Participants must meet one of the following criteria:\n\n   1. Recipient of prior myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplant using either bone marrow or peripheral blood stem cells or single or double cord blood OR\n   2. Primary immunodeficiency disorder (as defined by clinical and laboratory evaluations)81 and have not undergone HSCT, OR\n   3. Recipients of solid organ transplant.\n2. Documentation of chronic norovirus infection:\n\n   a. Chronic norovirus infections will be defined as having consecutive positive norovirus stool tests (2 or more) spanning a minimum three-month period with attributable signs and symptoms of norovirus disease.\n3. Participants receiving steroids for treatment of GVHD or for other reasons, dosage must have been tapered to \\\u003C0.5 mg\u002Fkg\u002Fday of prednisone (or equivalent) a minimum of 7 days prior to infusion.\n\n   a. Treatment with enteral topical steroids such as Budesonide at standard doses may be continued if previously utilized but should not be newly initiated in the 3 months after NST therapy.\n4. For participants who have undergone HSCT, participants must have stable donor chimerism within the 30 days prior to NST infusion.\n\n   a. Stability will be defined as i. \\>95% donor chimerism in CD33 and\u002For whole blood chimerism. OR ii. \\>90% donor chimerism with \\\u003C5% change between subsequent tests separated by at least 1 week.\n5. For recipients of solid organ transplants, participants must have stable graft function on maintenance immunosuppression, without evidence of rejection in the past 2 months prior to infusion, as defined by:\n\n   a. Stability of relevant functional testing in the previous 2 months, defined as: i. Renal transplant: renal function ≥ grade 3 per the National Kidney Foundation K\u002FDOQI Clinical Practice Guidelines for Chronic Kidney Disease (2002) ii. Cardiac transplant: maintenance of LVEF \\>40% iii. Lung transplant: lack of baseline oxygen requirement iv. Liver transplant: AST\u002FALT ≤3x upper limit normal and bilirubin ≤2x upper limit normal b. Donor-derived cell free DNA \\\u003C2x upper limits for assay in the previous 2 months, c. Stable donor-specific antibody profile in the previous 2 months. i. No increase in antibody titers between most recent testing in the previous 2 months and prior testing.\n6. Karnofsky\u002FLansky score \\>50\n7. 3 months to 80 years of age at enrollment.\n8. ANC ≥500\u002Ful.\n9. Hemoglobin ≥7.0g\u002Fdl (level can be achieved with transfusion).\n10. Platelets ≥20 K\u002Ful (level can be achieved with transfusion).\n11. Bilirubin ≤2x upper limit normal.\n12. AST ≤3x upper limit normal.\n13. Serum creatinine ≤2x upper limit normal OR estimated GFR ≥30 ml\u002Fhr.\n14. Pulse oximetry of ≥90% on room air.\n15. Negative pregnancy test in female participant of childbearing age.\n16. Written informed consent and\u002For signed assent line from participant, parent or guardian.\n\nDonor Inclusion Criteria:\n\n1. Donors who have fulfilled eligibility as per United States Food and Drug Administration (FDA) regulations outlined in 21 Code of Federal Regulations (CFR) 1271 subpart C. This includes that donors have been deemed in good health by donor physician based on physical examination and laboratory testing. If a donor has been chosen for the transplant based on urgent medical need, that same donor will also be used for NST generation provided that there are no new reasons for ineligibility since the stem cell collection.\n2. For third-party banking, donors must be between 2 to 35 years of age (females) or 2 to 40 years of age (males).\n3. Donor or guardian of pediatric donor capable of providing informed consent.\n4. Donor (related or unrelated) must have completed Infectious Disease (ID) testing up to 7 days before or after the collection of blood for NST manufacturing. The following tests will be performed:\n\n   * HBsAg\n   * HBc Antibody\n   * HCV Antibody\n   * HIV 1\u002F2 Antibody\n   * HTLV I\u002FII Antibody\n   * T. Cruzi Antibody (Chagas)\n   * CMV Total Antibody\n   * Syphilis (T. Pallidum IgG and IgM)\n   * HBV, HCV, HIV Nucleic Acid testing (NAT)\n   * WNV NAT\n5. Female donors of childbearing age must have a negative pregnancy test and not be lactating.\n\nExclusion Criteria:\n\nParticipants Exclusion Criteria for NST Infusion:\n\n1. Participants receiving biological or immunosuppressive monoclonal antibodies targeting T cells within 28 days prior to NST infusion, including ATG, Alemtuzumab, Basiliximab, Tocilizumab, Brentuximab, or other medications under this category as determined by the investigators.\n\n   a) If alemtuzumab has been received within 6 weeks prior to NST infusion, plasma levels should be obtained to ensure drug clearance (≤0.16 pg\u002Fml).\n2. Participants who have received donor lymphocyte infusion (DLI), chimeric antigen receptor T cell infusion, or other experimental cellular therapies within 28 days prior to NST infusion.\n3. Participants with SCID who have undergone α\u002Fβ TCR depleted HSCT within the past 100 days post-transplant.\n4. Participants who have received ruxolitinib or other JAK inhibitors within 7 days prior to NST infusion.\n5. Participants with uncontrolled or progressing infections other than norovirus. Uncontrolled infections are defined as bacterial, fungal, or non-targeted viral infections with either clinical signs of worsening despite standard therapy, or chronic gastrointestinal symptoms that may be attributed to the uncontrolled infection. Progressing infection is defined as hemodynamic instability, worsening physical signs, or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.\n\n   1. For bacterial infections, participants must be receiving definitive therapy and have no signs of progressing infection within 7 days prior to NST infusion and or no chronic gastrointestinal symptoms associated with this bacterial infection.\n   2. For fungal infections, participants must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection within 7 days prior to NST infusion.\n6. Participants must not have other active gastrointestinal infections to which symptoms may be attributable, including parasitic infections (cryptosporidium, giardiasis), viral infections aside from norovirus (CMV colitis, rotavirus, adenovirus), or bacterial infections with C. difficile, Yersinia, Campylobacter, Salmonella, Shigella, or enteroinvasive or enterotoxigenic E. coli.\n\n   a) Testing for unrelated gastrointestinal (GI) infections must be performed within 14 days prior to NST infusion, and must include: i. Crytosporidium\u002FGiardia testing via antigen or PCR testing. ii. Stool viral testing for rotavirus and adenovirus via antigen or PCR testing.\n\n   iii. Stool bacterial culture or PCR testing. iv. C. difficile toxin PCR. b) Determination of active infection versus chronic carriage\u002Fshedding will be made by the investigators and clinical providers and will depend on the presence of clinical symptoms corresponding with the timing of positive test results, presence of a clinical response to targeted therapy, and by histological or other testing if clinically indicated.\n7. Participants with active and uncontrolled relapse of malignancy (if applicable).\n\n   1. Failure of primary engraftment is defined as failure to achieve platelet and\u002For neutrophil engraftment (ANC \\\u003C500\u002Ful and\u002For platelets \\\u003C20 K\u002Ful) following HSCT.\n   2. Secondary graft failure is defined as \\\u003C5% donor chimerism (CD3+ or CD34+) or permanent loss of neutrophil and\u002For platelet engraftment (ANC \\\u003C500\u002Ful and\u002For platelets \\\u003C20 K\u002Ful) at any time after primary engraftment.\n8. Participants with symptomatic gastrointestinal conditions aside from norovirus, including active inflammatory bowel disease or graft versus host disease (grades 2 to 4).\n9. Participants who have received a small bowel transplant.\n10. Participants receiving checkpoint inhibitors within the previous 3 months prior to NST infusion, including nivolumab, pembrolizumab, or other related medications.\n11. For SOT recipients, alteration in immunosuppression as follows:\n\n    1. Any intensification of immunosuppression (including but not limited to pulse dose corticosteroids or new biologic therapies) in the previous 2 months,\n    2. Alteration of maintenance immunosuppression (including changes in the number of agents or dosing goals) in the previous month.\n12. Participants who have received enteral immunoglobulin, nitazoxanide, or other experimental therapies for norovirus infection within 28 days prior to NST infusion.\n13. Co-enrollment in other trials is restricted, other than enrollment on natural history or observational studies. Study staff should be notified of co-enrollment as it may require the approval of the investigator or sponsor.\n\nDonor Exclusion Criteria:\n\n1\\. Donation of cells would pose a physical or psychological risk to the donor","3 Months","80 Years",{"count":95,"type":21},48,[97],"PHASE1","This is a Phase I dose-escalation study to evaluate the safety of norovirus -specific T-cell (NST) therapy for chronic norovirus infection in participants following hematopoietic stem cell transplantation (HSCT) or who are immunocompromised due to PID and have not undergone HSCT, or Solid Organ Transplant (SOT) recipients.",[100,28,101],"Viral Infection","Primary Immunodeficiency Disorders (PID)","2026-01-23",{"date":104,"type":40},"2026-01-26",{"date":106,"type":40},"2022-03-17",{"date":108,"type":21},"2028-10-30",{"name":110,"class":47},"Children's National Research Institute",3,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":60,"phases":121,"briefSummary":122,"conditions":123,"keywords":125,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":48},"100619697","safety-and-efficacy-of-iptacopan-in-patients-with-high-risk-transplantation-associated-thrombotic-microangiopathy-100619697","NCT07347990","Safety and Efficacy of Iptacopan in Patients With High-Risk Transplantation-Associated Thrombotic Microangiopathy","A Prospective, Multicenter, Single-Arm Study: Safety and Efficacy of Iptacopan in the Treatment of High-Risk Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy (TA-TMA)","Inclusion Criteria:\n\n1. Age ≥12 years at the time of ICF signature.\n2. Previous recipient of autologous or allogeneic HSCT.\n3. Persistent TA-TMA despite initial management of potential triggers (e.g., CNI\u002FmTOR inhibitor reduction, infection or GVHD treatment), with TMA activity sustained for ≥72 hours post-intervention.\n4. TA-TMA diagnosis, confirmed ≤14 days prior to or during screening by either biopsy-proven microthrombi or ≥4 of the following:\n\n(1) LDH \\> ULN (2) Proteinuria (rUPCR ≥1 mg\u002Fmg) (3) Hypertension (age-adjusted) (4) New-onset thrombocytopenia (platelet decrease ≥50%, count ≤50,000\u002Fmm³, or transfusion-refractory) (5) New-onset anemia or increased transfusion need (6) Microangiopathy on blood smear (schistocytes ≥1%) or biopsy (7) Elevated terminal complement complex (C5b-9) 5. High-risk TMA features (per 2023 consensus), meeting ≥1 criterion:\n\n1. LDH ≥2× ULN\n2. Elevated sC5b-9\n3. Proteinuria (rUPCR ≥1 mg\u002Fmg)\n4. Multi-organ dysfunction syndrome (MODS)\n5. Concurrent Grade II-IV acute GVHD\n6. Active systemic infection 6. Able to receive oral medication. 7. Failure of first-line therapy (e.g., CNI\u002FmTOR inhibitor adjustment, plasma exchange, rituximab, defibrotide), excluding prior complement inhibitors.\n\n8\\. Life expectancy \\>8 weeks. 9. Required vaccination against encapsulated bacteria (meningococcal, pneumococcal) per local guidelines, administered ≥2 weeks prior to first dose. If vaccination is delayed, antimicrobial prophylaxis is required.\n\n10\\. For subjects unable to receive meningococcal vaccines, antibiotic prophylaxis must be continued throughout treatment and for 8 months post-last dose.\n\n11\\. For subjects of reproductive potential: agreement to use effective contraception and, for females, a negative pregnancy test at screening.\n\n12\\. Provision of signed informed consent and compliance with study procedures.\n\nExclusion Criteria:\n\n1. Known familial or acquired ADAMTS13 deficiency (activity \\\u003C5%).\n2. Known Shiga toxin-associated HUS (positive Shiga toxin assay or culture).\n3. Positive direct Coombs test with clinically significant immune-mediated hemolysis per investigator.\n4. Clinically overt disseminated intravascular coagulation (DIC) according to ISTH criteria.\n5. Bone marrow\u002Fgraft failure.\n6. Known HIV infection (confirmed by testing within 6 months prior to screening).\n7. Active meningococcal disease.\n8. Septic shock requiring vasopressor support within 7 days prior to enrollment.\n9. Pregnant or breastfeeding.\n10. Any concurrent or prior medical condition unrelated to TA-TMA that, in the opinion of the investigator or sponsor, could increase risk or confound study outcomes (e.g., significant cardiac, pulmonary, renal, endocrine, or hepatic disease).\n11. All-cause respiratory failure requiring mechanical ventilation within 72 hours prior to enrollment.\n12. Acute\u002Fchronic heart failure with left ventricular ejection fraction ≤40%.\n13. Prior treatment with iptacopan, eculizumab, or other complement inhibitors within 60 days before first study dose.\n14. Use of any investigational agent within 30 days or 5 half-lives (whichever is longer) prior to screening.\n15. Recurrent primary malignancy or post-transplant lymphoproliferative disorder (PTLD).",{"count":120,"type":21},30,[62],"The goal of this clinical trial is to evaluate the efficacy and safety of Iptacopan as a second-line treatment for high-risk hematopoietic stem cell transplantation-associated thrombotic microangiopathy (TA-TMA). Iptacopan is a selective oral small-molecule complement factor B inhibitor. It acts by inhibiting factor B, blocking the formation of C3 convertase, reducing C3b deposition, thereby suppressing C5 convertase (C3bBbC3b) and ultimately decreasing the formation of the membrane attack complex (MAC), which is expected to mitigate endothelial damage in TA-TMA pathology. The main questions this study aims to answer are:\n\n* Does Iptacopan improve 6-month overall survival in high-risk TA-TMA patients?\n* What adverse events do participants experience while taking Iptacopan?\n* Does Iptacopan provide hematological response and organ function recovery in TA-TMA patients? In this prospective, multicenter, open-label, single-arm Phase II study, all participants will receive Iptacopan treatment. The primary endpoint of this study is the 6-month overall survival rate from TA-TMA diagnosis. Secondary endpoints include safety evaluation, hematological response, and organ function recovery.\n\nDuring the study, participants will:\n\n* Receive Iptacopan treatment according to protocol\n* Undergo regular assessments for safety and efficacy monitoring\n* Be followed for up to 24 months post-treatment initiation",[124,28],"Thrombotic Microangiopathy",[126,127,128],"hematopoietic stem cell transplantation","transplantation-associated thrombotic microangiopathy","Iptacopan","NOT_YET_RECRUITING","2026-01-09",{"date":132,"type":40},"2026-01-16",{"date":134,"type":21},"2026-01-01",{"date":136,"type":21},"2029-12-31",{"name":138,"class":47},"First Affiliated Hospital of Zhejiang University",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":60,"phases":149,"briefSummary":150,"conditions":151,"keywords":152,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":84},"100612587","prehabilitation-to-improve-frailty-function-and-quality-of-life-in-candidates-for-hematopoietic-stem-cell-transplantation-100612587","NCT07255521","Prehabilitation to Improve Frailty, Function, and Quality of Life in Candidates for Hematopoietic Stem Cell Transplantation","Effects of a Prehabilitation Program on Frailty, Function, Quality of Life, and Post-Transplant Outcomes in Candidates for Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial","PREHAB-HSCT","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Diagnosis of hematologic malignancy requiring HSCT (autologous or allogeneic).\n* Minimum of ≥4 weeks available before the scheduled transplant.\n* \"Pre-frail\" or \"frail\" according to the HCT Frailty Scale.\n* ECOG ≤2 or Karnofsky ≥60.\n* Internet access (videocalls, Zoom platform, or a facilitator) for remote sessions.\n\nExclusion Criteria:\n\n* Cognitive impairment preventing questionnaire completion.\n* Musculoskeletal comorbidities preventing participation in supervised exercise-based prehabilitation.\n* Prior chemotherapy or radiotherapy not related to the hematologic malignancy.\n* Medical conditions limiting participation (e.g., unstable angina, arrhythmia, hypertension or heart failure, acute systemic infection with fever, acute myocarditis, or pericarditis).",{"count":148,"type":21},68,[62],"Candidates for hematopoietic stem cell transplantation (HSCT) frequently experience declines in strength, physical function, and quality of life before the procedure. Many also present fatigue, limitations in daily activities, and an increased risk of complications during and after hospitalization. Optimizing physical condition before transplantation may improve post-procedure recovery.\n\nThis study will evaluate whether a prehabilitation program improves physical function, frailty, and quality of life in adults preparing for HSCT. The intervention consists of supervised exercise, education, and activities designed to enhance endurance and functional capacity. Although prehabilitation has shown benefits in other oncologic populations, it has been minimally studied in HSCT candidates, and no structured programs have been evaluated in Chile.\n\nA total of 68 adults will be randomly assigned to a prehabilitation group or a usual-care control group. The prehabilitation group will receive a personalized program including aerobic and resistance exercise, stretching, balance training, respiratory exercises, and education on healthy behaviors, delivered through a hybrid model of in-person and remote sessions. Occupational therapy will also be provided to support functional and cognitive abilities. The control group will continue with standard medical care.\n\nBaseline and post-intervention assessments will include measures of strength, frailty, fatigue, balance, cognitive function, daily activities, and quality of life. Post-transplant outcomes such as hospital length of stay, complications, and readmissions within three months will also be recorded. Feasibility, adherence, satisfaction, and adverse events will be evaluated.\n\nFindings from this trial may inform the development of structured prehabilitation programs for HSCT candidates and support the implementation of evidence-based supportive care strategies in hematologic oncology.",[28],[153,154,155,156,157,158,159,160],"Prehabilitation","Hematologic Malignancies","Frailty","Cancer-Related Frailty","Functional capacity","Physical Function","Quality of life","Post-Transplant Outcomes","2025-12-07",{"date":163,"type":40},"2025-12-15",{"date":165,"type":21},"2025-12-26",{"date":167,"type":21},"2026-06-30",{"name":169,"class":47},"Hospital del Salvador",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":178,"targetDuration":180,"studyType":22,"phases":4,"briefSummary":181,"conditions":182,"keywords":197,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":48},"100608743","high-altitude-hematology-observation-stem-cell-transplantation-halo-sct-100608743","NCT07205523","High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)","High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT): A Prospective Real-World Cohort Study in the Qinghai-Tibet Plateau","HALO-SCT","Inclusion Criteria:\n\n1. Patients diagnosed with hematologic diseases who are admitted to the HSCT center of Qinghai University Affiliated Hospital on or after September 1, 2023.\n2. Planned or actual hematopoietic stem cell transplantation (HSCT).\n3. Provision of signed informed consent.\n\nExclusion Criteria:\n\n1. Inability to provide long-term follow-up data due to severe comorbidities or logistical reasons.\n2. Substance abuse compromising adherence.\n3. Any condition judged by investigators to jeopardize safety or compliance.",{"count":179,"type":21},1000,"100 Years","The High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT) study is the first prospective real-world cohort of hematologic diseases and transplantation in the Qinghai-Tibet Plateau. Patients undergoing hematopoietic stem cell transplantation (HSCT) at Qinghai University Affiliated Hospital, together with their donors, are systematically enrolled. The registry collects demographic, diagnostic, treatment, prognosis, and medical expense information, as well as biospecimens for future analyses. Historical data are incorporated, and prospective data collection is ongoing with long-term follow-up planned. The registry is designed as a sustainable research infrastructure to provide comprehensive data on disease incidence, treatment patterns, outcomes, and resource utilization in a high-altitude setting.",[28,183,184,185,186,187,188,189,190,191,192,193,194,195,196],"Acute Myeloid Leukemia (AML)","Leukemias, Acute Myeloid","Myeloid Leukemias, Acute","Hemophilia","Myelodysplastic Syndrome","MDS","Lymphoma","Leukemia","Aplastic Anemia","Bleeding Disorders","Bone Marrow Transplantation","Multiple Myeloma","Myeloma, Multiple","Immune Reconstitution",[198],"High-altitude Bone marrow transplantation Allogeneic HSCT Autologous HSCT Immune reconstitution Graft-versus-host disease Relapse Survival Quality of life","2025-09-25",{"date":201,"type":40},"2025-10-03",{"date":203,"type":40},"2023-09-01",{"date":205,"type":21},"2100-12-31",{"name":207,"class":47},"Yigeng Cao,MD,PhD",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":60,"phases":217,"briefSummary":218,"conditions":219,"keywords":222,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":48},"100597665","effects-of-different-inspiratory-muscle-training-protocols-in-hematopoietic-stem-cell-transplant-recipients-100597665","NCT07061444","Effects of Different Inspiratory Muscle Training Protocols in Hematopoietic Stem Cell Transplant Recipients","Inclusion Criteria:\n\n* Planned haematopoietic stem cell transplantation in the adult bone marrow transplant unit\n* Between the ages of 18-65\n* Under standard medical treatment, including immunosuppressives, antibiotics and other medications\n* Ability to walk, co-operate and be clinically stable\n* No history of orthopaedic, neurological, cardiac disorders\n\nExclusion Criteria:\n\n* Cognitive disorders\n* Have orthopaedic or neurological diseases that may affect the assessment of physical fitness tests\n* Having comorbidities such as asthma, COPD\n* Conditions in which exercise training is contraindicated, such as acute bleeding, haemoglobin value \\\u003C5 g\u002Fdl, platelet count ≤10000 mm3, high fever (body temperature \\>38◦C), severe pain, confusion, dizziness, nausea and vomiting\n* Patients with pneumonia or any acute infection\n\n  -≥ 3 consecutive sessions of interruption of the exercise group subjects' attendance to the training protocol\n* Loss of willingness to participate in the research during the research process\n* Development of clinical haemodynamic instability in patients","65 Years",{"count":216,"type":21},45,[62],"Introduction: After haematopoietic stem cell transplantation (HSCT), patients often experience complications such as respiratory difficulties, fatigue and decreased quality of life.\n\nThe aim of the study was to compare the effectiveness of different inspiratory muscle training (IMT) protocols on respiratory muscle strength and endurance, dyspnoea, maximal exercise capacity, diaphragmatic function, respiratory function parameters, peripheral muscle strength, fatigue, quality of life, oxidative stress parameters, muscle biomarkers and inflammatory biomarkers in HSCT recipients during the transplantation process.\n\nMethod: The study will include patients between 18-65 years of age, who are able to walk and understand the instructions, who do not have orthopedic, neurological or cardiac disorders and who will undergo haematopoietic stem cell transplantation. Patients with cognitive impairments; orthopedic or neurological diseases that may affect the evaluation of physical fitness tests; patients with comorbidities such as asthma, COPD will not be included in the study. In cases where the exercise group subjects' attendance to the training protocol is interrupted for 3 sessions or more consecutively, the voluntariness to participate in the research is lost during the research process, and clinical haemodynamic instability develops in the subjects, the participant will be excluded from the study. Patients in whom exercise training is contraindicated such as acute bleeding, haemoglobin value \\\u003C5 g\u002Fdl, platelet count ≤10000 mm3, high fever (body temperature \\>38◦C), severe pain, confusion, dizziness, nausea and vomiting will not be included in the exercise.\n\nIt is planned as a prospective, randomised controlled and single blinded study. Triple blinding could not be performed due to the executive's evaluation and implementation of the study protocol. Patients included in the study will be randomly divided into 3 study groups of 15 people each. Stratified randomisation technique will be used. A total of 45 haematopoietic stem cell transplant patients will be included in the study. Patients will be evaluated 3 times: before exercise therapy (pre-HSCT), before and after starting the preparatory regime and after exercise therapy (post-HSCT). Primary assessment measures are dyspnoea, maximal exercise capacity, respiratory muscle strength and endurance, diaphragmatic respiration, oxidative stress parameters, inflammatory markers, muscle biomarkers, pulmonary function test. Secondary assessment measures were peripheral muscle strength, fatigue, depression, and quality of life.\n\nThe research arms consisted of a total of 45(15;15;15) people in 3 groups: 'standard inspiratory muscle training group', 'functional respiratory muscle training group' and 'control group' with 15 people in each group. All patients in the control and research groups will receive inspiratory muscle training for a total of 30 minutes twice a day, every weekday during the transplantation period, starting at the end of the session in which their initial assessment was made. Functional respiratory muscle training group will perform functional exercises simultaneously with inspiratory muscle training 3 days a week (Monday-Wednesday-Friday or Tuesday-Thursday-Saturday). All exercises will be supervised by a physiotherapist.\n\nThe most important originality of this study is that it is the first study to investigate the effects of functional respiratory muscle training on respiratory parameters, diaphragm function, peripheral muscle strength, maximum oxygen consumption, dyspnoea, fatigue, depression and quality of life in HSCT recipients. It is the first randomised controlled study to demonstrate the effect of inspiratory muscle training on diaphragmatic function in HSCT recipients and it is one of the rare studies in which exercise capacity will be evaluated by cardiopulmonary exercise test. It is also the first study to examine the relationship between inspiratory muscle training and muscle biomarkers and oxidative stress parameters in HSCT recipients.\n\nH0: There is no difference in the effectiveness of different inspiratory muscle training protocols on maximal exercise capacity, respiratory muscle strength, respiratory muscle endurance, diaphragmatic function, oxidative stress parameters, muscle biomarkers, inflammatory biomarkers, dyspnoea, peripheral muscle strength, quality of life, fatigue, depression in haematopoietic stem cell transplant recipients.\n\nH1: There is a difference in the effectiveness of different inspiratory muscle training protocols on maximal exercise capacity, respiratory muscle strength, respiratory muscle endurance, diaphragmatic function, oxidative stress parameters, muscle biomarkers, inflammatory biomarkers, dyspnoea, peripheral muscle strength, quality of life, fatigue, depression in haematopoietic stem cell transplant recipients.",[28,220,221],"Pulmonary Rehabilitation","Inspiratory Muscle Training",[223,224,126,225,226],"inspiratory muscle training","pulmonary rehabilitation","respiratory therapy","respiratory muscle","2025-07-02",{"date":229,"type":40},"2025-07-11",{"date":231,"type":21},"2025-08-02",{"date":233,"type":21},"2026-09-02",{"name":235,"class":47},"Ceren Derya Gültekin",{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":17,"minAge":243,"maxAge":244,"enrollmentInfo":245,"targetDuration":4,"studyType":60,"phases":247,"briefSummary":250,"conditions":251,"keywords":4,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":261,"locationsCount":4},"100596972","phase-2-vendacbu2flu4-vs-bu2flu5-conditioning-regimen-for-elderly-myeloid-malignancies-undergoing-allo-hsct-100596972","NCT07052422","VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT","Venetoclax+Decitabine+Busulfan+Fludarabine (VEN+DAC+Bu2Flu4) vs Busulfan+Fludarabine Conditioning Regimen (Bu2Flu5 ) for Older Patients With Myeloid Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)","Inclusion Criteria:\n\n* 60-75 years\n* Acute myeloid leukaemia in first complete remission or myelodysplastic syndrome\n* Willing to undergo the first allo-HSCT\n* Eastern Cooperative Oncology Group performance status of 0-2\n\nExclusion Criteria:\n\n* Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)\n* Patients with any conditions not suitable for the trial (investigators' decision)","60 Years","75 Years",{"count":246,"type":21},160,[248,249],"PHASE2","PHASE3","The purpose of this study is to compare the efficacy and safety of venetoclax+decitabine+busulfan+fludarabine (VEN+DAC+Bu2Flu4) regimen with busulfan+fludarabine (Bu2Flu5) regimen in older patients with myeloid malignancies undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).",[252,253,254,28],"Older Patients","Myeloid Malignancies","Conditioning","2025-07-01",{"date":257,"type":40},"2025-07-04",{"date":259,"type":21},"2025-07-15",{"date":136,"type":21},{"name":262,"class":47},"Nanfang Hospital, Southern Medical University"]